Among these, stimulator of interferon genes (STING) agonists have garnered particular interest due to their ability to initiate robust type I interferon (IFN-I) response, thereby stimulating immune cell activation and infiltration within the tumor microenvironment (TME) (2, 3). Here, STING1 is linked to neoplasm.